JD III - Lineage Cell General Secretary
| LCTX Stock | USD 0.52 0.09 14.75% |
Executive
JD III is General Secretary of Lineage Cell Therapeutics
| Age | 43 |
| Address | 2173 Salk Avenue, Carlsbad, CA, United States, 92008 |
| Phone | 442 287 8990 |
| Web | https://www.lineagecell.com |
Lineage Cell Management Efficiency
The company has return on total asset (ROA) of (0.1286) % which means that it has lost $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3504) %, meaning that it created substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.31 in 2024. At this time, Lineage Cell's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 65.7 M in 2024, whereas Total Current Assets are likely to drop slightly above 21.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| MPH DO | Kronos Bio | 59 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Colin Love | Replimune Group | 66 | |
| Kevin Shaw | NextCure | 49 | |
| MRCP MD | Coherus BioSciences | 55 | |
| Michael CPA | Nuvectis Pharma | 48 | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Justin Fairchild | Portage Biotech | N/A | |
| David House | Armata Pharmaceuticals | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| MBA JD | Ovid Therapeutics | 58 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Moses Makunje | Nuvation Bio | 45 | |
| Paul Reider | Coherus BioSciences | 54 | |
| Linda Moreira | MAIA Biotechnology | N/A | |
| MBA MD | Replimune Group | 58 | |
| Zhong Zhong | Ovid Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.13 |
Lineage Cell Therapeutics Leadership Team
Elected by the shareholders, the Lineage Cell's board of directors comprises two types of representatives: Lineage Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lineage. The board's role is to monitor Lineage Cell's management team and ensure that shareholders' interests are well served. Lineage Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lineage Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charlotte Hubbert, Vice Development | ||
| Jill Howe, CFO Officer | ||
| DVM Dvm, VP Affairs | ||
| Alexandra Hernandez, Senior Controller | ||
| William MBA, President Corporation | ||
| JD III, General Secretary | ||
| Ioana Hone, Director Relations | ||
| William Annett, Pres Corp | ||
| Rami Skaliter, Chief Neurosciences | ||
| Harold Waitz, Vice Control | ||
| MBA MA, President CEO |
Lineage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lineage Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | 84.66 M | ||||
| Shares Outstanding | 220.42 M | ||||
| Shares Owned By Insiders | 0.44 % | ||||
| Shares Owned By Institutions | 50.56 % | ||||
| Number Of Shares Shorted | 15.94 M | ||||
| Price To Earning | 3.62 X | ||||
| Price To Book | 2.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.